| 摘要 |
<p>Provided are an anticancer sensitivity-determining marker by which responsiveness to treatment of individual patients can be discriminated and a novel cancer treatment means using the same. A marker for determining the sensitivity to an anticancer drug including oxaliplatin or a salt thereof and fluorouracil or a salt thereof, comprises at least one molecule selected from an amino acid metabolic substance, a nucleic acid metabolic substance, a pentose phosphate pathway substance, a glycolysis substance, a TCA cycle substance, a polyamine metabolic substance, and substances involved in the metabolic system associated with 7,8-Dihydrobiopterin, 6-Phosphogluconic acid, butyric acid, triethanolamine, 1-methylnicotinamide, NADH, NAD+ and molecules thereof.</p> |
